[go: up one dir, main page]

WO2007018671A3 - Compositions et methodes de traitement d'etats associes a la signalisation de l'ephrine au moyen de cupredoxines - Google Patents

Compositions et methodes de traitement d'etats associes a la signalisation de l'ephrine au moyen de cupredoxines Download PDF

Info

Publication number
WO2007018671A3
WO2007018671A3 PCT/US2006/019684 US2006019684W WO2007018671A3 WO 2007018671 A3 WO2007018671 A3 WO 2007018671A3 US 2006019684 W US2006019684 W US 2006019684W WO 2007018671 A3 WO2007018671 A3 WO 2007018671A3
Authority
WO
WIPO (PCT)
Prior art keywords
cupredoxins
compositions
methods
conditions related
treating conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/019684
Other languages
English (en)
Other versions
WO2007018671A2 (fr
Inventor
Ananda Chakrabarty
Gupta Tapas Das
Tohru Yamada
Anita Chaudhari
Arsenio Fialho
Yonghua Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois at Urbana Champaign
University of Illinois System
Original Assignee
University of Illinois at Urbana Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Priority to MX2007014598A priority Critical patent/MX2007014598A/es
Priority to CA002608512A priority patent/CA2608512A1/fr
Priority to BRPI0612424-0A priority patent/BRPI0612424A2/pt
Priority to AU2006277009A priority patent/AU2006277009A1/en
Priority to JP2008512587A priority patent/JP2008539795A/ja
Application filed by University of Illinois at Urbana Champaign, University of Illinois System filed Critical University of Illinois at Urbana Champaign
Priority to EP06813192A priority patent/EP1888106A4/fr
Publication of WO2007018671A2 publication Critical patent/WO2007018671A2/fr
Priority to IL187138A priority patent/IL187138A0/en
Anticipated expiration legal-status Critical
Publication of WO2007018671A3 publication Critical patent/WO2007018671A3/fr
Priority to NO20076391A priority patent/NO20076391L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des compositions et des méthodes d'utilisation de cuprédoxines, et de variants, de dérivés et d'équivalents structuraux de cuprédoxines qui interfèrent avec le système de signalisation de l'éphrine dans des cellules mammifères. De manière spécifique, l'invention concerne des compositions et des méthodes faisant intervenir des cuprédoxines, de type azurine, rusticyanine et plastocyanine, et des variants, dérivés et équivalents structuraux associés, pour le traitement du cancer chez des mammifères.
PCT/US2006/019684 2005-05-20 2006-05-19 Compositions et methodes de traitement d'etats associes a la signalisation de l'ephrine au moyen de cupredoxines Ceased WO2007018671A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP06813192A EP1888106A4 (fr) 2005-05-20 2006-05-19 Compositions et méthodes de traitement d'états associés à la signalisation de l'éphrine au moyen de cuprédoxines
CA002608512A CA2608512A1 (fr) 2005-05-20 2006-05-19 Compositions et methodes de traitement d'etats associes a la signalisation de l'ephrine au moyen de cupredoxines
BRPI0612424-0A BRPI0612424A2 (pt) 2005-05-20 2006-05-19 composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas
AU2006277009A AU2006277009A1 (en) 2005-05-20 2006-05-19 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
JP2008512587A JP2008539795A (ja) 2005-05-20 2006-05-19 キュプレドキシンを用いたエフリン信号伝達に関する症状を治療するための組成物および方法
MX2007014598A MX2007014598A (es) 2005-05-20 2006-05-19 Composiciones y metodos para tratar condiciones relacionadas con senalizacion de efrina con cupredoxinas.
IL187138A IL187138A0 (en) 2005-05-20 2007-11-04 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
NO20076391A NO20076391L (no) 2005-05-20 2007-12-11 Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US68281205P 2005-05-20 2005-05-20
US60/682,812 2005-05-20
US11/244,105 2005-10-06
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US76474906P 2006-02-03 2006-02-03
US60/764,749 2006-02-03

Publications (2)

Publication Number Publication Date
WO2007018671A2 WO2007018671A2 (fr) 2007-02-15
WO2007018671A3 true WO2007018671A3 (fr) 2007-11-22

Family

ID=37727776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/019684 Ceased WO2007018671A2 (fr) 2005-05-20 2006-05-19 Compositions et methodes de traitement d'etats associes a la signalisation de l'ephrine au moyen de cupredoxines

Country Status (10)

Country Link
EP (1) EP1888106A4 (fr)
JP (1) JP2008539795A (fr)
KR (1) KR20080040631A (fr)
AU (1) AU2006277009A1 (fr)
BR (1) BRPI0612424A2 (fr)
CA (1) CA2608512A1 (fr)
IL (1) IL187138A0 (fr)
MX (1) MX2007014598A (fr)
NO (1) NO20076391L (fr)
WO (1) WO2007018671A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7691383B2 (en) 2004-10-07 2010-04-06 The Board Of Trustees Of The University Of Illinois Cupredoxin derived transport agents and methods of use thereof
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
EP1904081A4 (fr) * 2005-07-19 2008-12-03 Univ Illinois Compositions et methodes de controle de angiogenese a l'aide de cupredoxines
JP2009502135A (ja) 2005-07-19 2009-01-29 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 血液脳関門を越えるための、および脳癌細胞内への輸送因子、並びにその使用方法
WO2008033987A2 (fr) * 2006-09-14 2008-03-20 The Board Of Trustees Of The University Of Illinois Compositions et procédés de prévention du cancer avec des cupredoxines
EP2117573A4 (fr) * 2007-01-11 2011-02-16 Univ Illinois Compositions et méthodes permettant de traiter des affections associées à la signalisation de l'éphrine avec des cuprexodines et des mutants de celles-ci
PL2199390T3 (pl) 2007-08-30 2017-06-30 Daiichi Sankyo Company, Limited Przeciwciało anty-epha2
KR101102829B1 (ko) * 2008-09-12 2012-01-05 재단법인 제주테크노파크 구멍갈파래 추출물과 그것의 항염증제로서의 용도
CN110090295B (zh) * 2018-01-29 2022-12-23 武汉康理通科技有限公司 Ephrin-B1在制备治疗炎症性肠病的药物中的用途
EP4511052A2 (fr) * 2022-04-22 2025-02-26 University of Miami Peptides mimétiques de ligand d'éphrine pour le traitement de maladies neurodégénératives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076380A2 (fr) * 2001-02-15 2002-10-03 The Board Of Trustees Of The University Of Illinois Facteurs cytotoxiques destines a moduler la mort cellulaire
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PUNJ V. ET AL.: "Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer", ONCOGENE, vol. 23, 2004, pages 2367 - 2378, XP003018759 *

Also Published As

Publication number Publication date
KR20080040631A (ko) 2008-05-08
NO20076391L (no) 2008-02-15
AU2006277009A1 (en) 2007-02-15
IL187138A0 (en) 2008-02-09
CA2608512A1 (fr) 2007-02-15
WO2007018671A2 (fr) 2007-02-15
EP1888106A4 (fr) 2009-01-14
JP2008539795A (ja) 2008-11-20
BRPI0612424A2 (pt) 2009-01-27
EP1888106A2 (fr) 2008-02-20
MX2007014598A (es) 2008-02-07

Similar Documents

Publication Publication Date Title
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
NO20076391L (no) Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
WO2010138820A3 (fr) Composés de n,n'-diarylurée et de n,n'-diarylthiourée utilisés en tant qu'inhibiteurs de l'initiation de la traduction
WO2007111948A3 (fr) Inhibiteurs de prényltransférases protéiques
BR112014015909A8 (pt) composição
WO2010018563A3 (fr) Compositions et procédés de pronostic d'un lymphome
AU2009209251A8 (en) Stabilized Angiopoietin-2 antibodies and uses thereof
MX2010009951A (es) Metodos, composiciones y kits para tratar dolor y prurito.
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
WO2007126799A3 (fr) Compositions et procédés d'utilisation associés à des anticorps de c-met
GB201020995D0 (en) Biological materials and uses thereof
WO2008085962A3 (fr) Méthodes de culture cellulaire destinées à la production de protéines recombinées en présence de niveaux réduits d'un ou plusieurs contaminants
WO2008011071A3 (fr) Interactions des voies de signaux hedgehog et du récepteur x hépatique
WO2010039802A3 (fr) Procédés et compositions pour isoler un acide nucléique
WO2009070244A3 (fr) Procédés d'inhibition de la fascine
WO2012061502A3 (fr) Polymorphismes génétiques associés à la thrombose veineuse et la réponse à la statine, procédés de détection et utilisations de ceux-ci
WO2007081966A3 (fr) Petites molécules pour traiter un cancer et des troubles de prolifération cellulaire anormale
WO2007120787A3 (fr) Procede de traitement, de diagnostic ou de detection du cancer
WO2009153774A3 (fr) Compositions et procédés pour le pronostic du cancer des ovaires
WO2012006068A3 (fr) Composés pour inhiber la prolifération cellulaire
WO2008137716A3 (fr) Sous-systèmes et procédés pour une utilisation dans des systèmes de patch-clamp
WO2008033887A3 (fr) Procédés de traitement du cancer
WO2010096754A8 (fr) Compositions et procédés pour prévenir et/ou traiter un cancer par pa-card
WO2009126335A3 (fr) Composés inhibiteurs d’ant2 et procédés d’utilisation de ceux-ci

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680017470.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006277009

Country of ref document: AU

Ref document number: 563048

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 187138

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2608512

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1907/MUMNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008512587

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/014598

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006277009

Country of ref document: AU

Date of ref document: 20060519

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006813192

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077028984

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007147467

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0612424

Country of ref document: BR